Piramal Pharma Limited (NSE:PPLPHARMA)

Piramal Pharma Statistics

Total Valuation

Piramal Pharma has a market cap or net worth of INR 181.30 billion. The enterprise value is 222.37 billion.

Market Cap	181.30B
Enterprise Value	222.37B

Important Dates

The next estimated earnings date is Thursday, May 14, 2026.

Earnings Date	May 14, 2026
Ex-Dividend Date	Jul 16, 2025

Share Statistics

Piramal Pharma has 1.33 billion shares outstanding. The number of shares has decreased by -0.55% in one year.

Current Share Class	1.33B
Shares Outstanding	1.33B
Shares Change (YoY)	-0.55%
Shares Change (QoQ)	-0.05%
Owned by Insiders (%)	0.19%
Owned by Institutions (%)	24.49%
Float	611.35M

Valuation Ratios

PE Ratio	n/a
Forward PE	82.54
PS Ratio	2.04
PB Ratio	2.25
P/TBV Ratio	4.65
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	0.74

Enterprise Valuation

EV / Earnings	-135.92
EV / Sales	2.51
EV / EBITDA	21.08
EV / EBIT	96.43
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	0.60
Debt / EBITDA	4.87
Debt / FCF	n/a
Interest Coverage	0.48

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	-4.27%
Return on Capital Employed (ROCE)	n/a
Weighted Average Cost of Capital (WACC)	-1.37%
Revenue Per Employee	16.20M
Profits Per Employee	-298,776
Employee Count	5,476
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Piramal Pharma has paid 2.17 billion in taxes.

Income Tax	2.17B
Effective Tax Rate	404.45%

Stock Price Statistics

The stock price has decreased by -39.18% in the last 52 weeks. The beta is 0.00, so Piramal Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.00
52-Week Price Change	-39.18%
50-Day Moving Average	153.93
200-Day Moving Average	182.97
Relative Strength Index (RSI)	38.19
Average Volume (20 Days)	3,444,579

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Piramal Pharma had revenue of INR 88.71 billion and -1.64 billion in losses. Loss per share was -1.24.

Revenue	88.71B
Gross Profit	54.10B
Operating Income	1.71B
Pretax Income	537.40M
Net Income	-1.64B
EBITDA	9.54B
EBIT	1.71B
Loss Per Share	-1.24

Balance Sheet

The company has 7.44 billion in cash and 48.51 billion in debt, with a net cash position of -41.07 billion or -30.93 per share.

Cash & Cash Equivalents	7.44B
Total Debt	48.51B
Net Cash	-41.07B
Net Cash Per Share	-30.93
Equity (Book Value)	80.74B
Book Value Per Share	61.03
Working Capital	n/a

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Depreciation & Amortization	7.84B
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 60.98%, with operating and profit margins of 1.92% and -1.84%.

Gross Margin	60.98%
Operating Margin	1.92%
Pretax Margin	0.61%
Profit Margin	-1.84%
EBITDA Margin	10.76%
EBIT Margin	1.92%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 0.14, which amounts to a dividend yield of 0.10%.

Dividend Per Share	0.14
Dividend Yield	0.10%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	2
Payout Ratio	n/a
Buyback Yield	0.55%
Shareholder Yield	0.65%
Earnings Yield	-0.90%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1